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The nigrostriatal dopaminergic system is implicated in action control and learning. A large
body of work has focused on the contribution of this system to modulation of the corticos-
triatal synapse, the predominant synapse type in the striatum. Signaling through the D2
dopamine receptor is necessary for endocannabinoid-mediated depression of corticostri-
atal glutamate release. Here we review the known details of this mechanism and discuss
newly discovered signaling pathways interacting with this system that ultimately exert
dynamic control of cortical input to the striatum and striatal output. This topic is timely
with respect to Parkinson’s disease given recent data indicating changes in the striatal
endocannabinoid system in patients with this disorder.
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ENDOCANNABINOIDS AND SYNAPTIC PLASTICITY
Discovery of the cannabinoid signaling system grew out of
studies of the actions of cannabis-derived drugs that contain
Δ9-Tetrahyrocannabinol (Δ 9-THC). The discovery of a Δ9-
THC-activated G protein-coupled receptor (GPCR), termed the
cannabinoid 1 or CB1 receptor (Matsuda et al., 1990), stimulated
the search for endogenous ligands (endocannabinoids, eCBs) that
could activate the receptor. Eventually, two lipid metabolites were
found to have CB1 agonist action. Arachidonoyl ethanolamide
(AEA or anandamide) is derived from phosphatidylethanolamide,
with several potential synthesis pathways described in the litera-
ture (Devane et al., 1992;DiMarzo et al., 1994; Liu et al., 2008). The
other major endocannabinoid, 2-arachidonoyl-glycerol (2-AG) is
produced frommembrane lipids via a two-stage reaction catalyzed
by phospholipase C and diacylglycerol lipase (DAGL; Mechoulam
et al., 1995). Enzymes that catalyze the breakdown of AEA (fatty
acid amide hydrolase, FAAH) and 2-AG (monoacylglycerol lipase)
have also been characterized. Both eCBs are known to activate CB1
receptors, and the other known cannabinoid receptor termedCB2,
and act throughout the body and brain. It is worth noting, how-
ever, that AEA has been reported to have many additional actions,
most notably acting as an agonist for the vanilloid-activated tran-
sient receptor potential vanilloid 1 (TRPV1) channel (Zygmunt
et al., 1999; Smart et al., 2000).
The CB1 receptor couples to the Gi/o subtypes of G-proteins.
Like the other Gi/o-activating GPCRs, CB1 receptors inhibit
adenylyl cyclase, activate G-protein-activated potassium chan-
nels (GIRKs), inhibit voltage-gated calcium channels (VGCCs),
and inhibit neurotransmitter release (Howlett and Fleming, 1984;
Howlett et al., 1986; Ishac et al., 1996; Jin et al., 1999). Within the
central nervous system, including the striatum, CB1 receptors are
located almost exclusively on presynaptic axon terminals (Katona
et al., 1999; Rodriguez et al., 2001;Mátyás et al., 2006). It is thus not
surprising that the most appreciated function of these receptors
is to inhibit neurotransmitter release. Within the striatum, presy-
naptic CB1 receptors are found on GABAergic and glutamatergic
axon terminals. Activation of CB1with synthetic agonists has been
shown to inhibit release of GABA, glutamate, and dopamine (DA)
within the striatum (Cadogan et al., 1997; Szabo et al., 1998; Kath-
mann et al., 1999;Gerdeman andLovinger,2001; Sidló et al., 2008),
although the effects onDA release appear to involve indirect effects
of other neurotransmitters (Sidló et al., 2008).
eCBs and CB1 receptors are also implicated in several forms
of synaptic plasticity involving presynaptic expression mecha-
nisms. There are three common forms: depolarization-induced
suppression of excitatory or inhibitory transmission (DSE/DSI),
short-term depression (STD) activated by Gq-coupled postsy-
naptic metabotropic receptors, and long-term depression (LTD;
Lovinger, 2008; Heifets and Castillo, 2009). The time courses
of these synaptic depressant phenomena differ, with DSE/DSI
and STD persisting only as long as the eCB signal acts on CB1
receptors, while LTD continues indeﬁnitely even after CB1 activa-
tion is terminated (Lovinger, 2008; Heifets and Castillo, 2009). It
should be noted that the mechanisms involved in DSE/DSI and
STD can interact, such that activation of metabotropic recep-
tors can increase the magnitude and extend the time course of
depolarization-induced synaptic suppression (Varma et al., 2001;
Brenowitz and Regehr, 2005). One common feature of all of these
forms of eCB-mediated synaptic depression is the need for a
postsynaptic stimulus, followed by a presynaptic CB1-mediated
synaptic depression. Thus, eCB-mediatedDSE/DSI, STD, and LTD
have been categorized as involving“retrograde signaling,”a type of
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synaptic plasticity that has come to be appreciated as widespread
in the nervous system (Wilson and Nicoll, 2001; Kano et al., 2009).
DA ROLES IN CORTICOSTRIATAL SYNAPTIC PLASTICITY
CORTICOSTRIATAL SHORT-TERM DEPRESSION
The dorsal striatum is the entry nucleus for basal ganglia process-
ing of cortical information. Cortical ﬁbers innervate the striatum
and synapse on striatal medium spiny neurons (MSNs), release
glutamate and, therefore, drive the activity of these GABAergic
projection cells. As such, the corticostriatal synapse represents a
crucial, initial step in the complex series of mechanisms under-
lying basal ganglia control of actions. Indeed, aberrant corticos-
triatal function is implicated in a variety of basal ganglia disor-
ders, including Parkinson’s disease (PD), Huntington’s disease,
obsessive-compulsive disorder, and addiction (Ingham et al., 1989;
Calabresi et al., 1992; Berke and Hyman, 2000; Klapstein et al.,
2001; Zaja-Milatovic et al., 2005; Welch et al., 2007). Investiga-
tion over the past quarter century has revealed that glutamatergic
signaling at the corticostriatal synapse is tightly modulated by a
complex array of neurotransmitters and cognate receptors located
on either presynaptic or postsynaptic elements. The eCBs have
emerged as important modulators of these inputs. The ﬁnding
that CB1 activation depresses corticostriatal glutamatergic synap-
tic transmission (Gerdeman and Lovinger, 2001; Huang et al.,
2001), provides one mechanism contributing to intrastriatal CB1
agonist injection-induced hypomotility and catalepsy (Gough and
Olley, 1978).
Within the striatum there is evidence for expression of sev-
eral types of eCB-dependent synaptic depression. Studies to date
have focused on characterizing plasticity at synapses onto MSNs.
Although eCB-mediated DSE/DSI have proven rather difﬁcult to
measure (Kreitzer and Malenka, 2005; Narushima et al., 2006a),
direct activation of metabotropic receptors, such as neurotensin
I, appear to be sufﬁcient to induce STD at glutamatergic synapses
onto MSNs (Yin et al., 2008).
Several studies have examined actions of D2 receptors on stri-
atal glutamatergic transmission with mixed results. The majority
of reports indicate that D2 activation has little effect when affer-
ents are activated at low frequencies, while synaptic depression
can be induced when D2 agonists are applied in conjunction
with more frequent afferent stimulation or during generalized
depolarization (Brown and Arbuthnott, 1983; Hsu et al., 1995;
Flores-Hernández et al., 1997; Calabresi et al., 1999; Bamford et al.,
2004a; Yin and Lovinger, 2006). One interpretation of these ﬁnd-
ings is that presynaptic D2 heteroceptors located on glutamatergic
terminals selectively suppress inputs from highly active afferents
(Bamford et al., 2004b). An alternative idea is that the combi-
nation of D2 activation and elevated afferent activity stimulates
production of eCBs that then inhibit synaptic transmission (Kre-
itzer and Malenka, 2005; Yin and Lovinger, 2006). Manipulations
of postsynaptic calcium levels and signaling mechanisms prevent
D2-induced synaptic depression, while expression of this depres-
sion likely involves a presynaptic decrease in glutamate release
probability (Yin and Lovinger, 2006).
Thus, a retrograde signaling role for eCBs has been postulated
to underlie this synaptic depression. Recent studies from the Cal-
abresi laboratory suggest that adenosine activation of adenosine
A2A receptors is one factor that suppresses D2 receptor-stimulated
eCB production (Tozzi et al., 2007). Blockade of these receptors,
which occurs after consumption of caffeinated beverages, relieves
this suppression. This allows for eCB-mediated synaptic depres-
sion even when glutamatergic afferents are activated only at low
frequencies. This interesting ﬁnding suggests one way in which
striatal A2A receptors may participate in striatal-based learning
and memory (Yu et al., 2009). Synaptic depression induced by
activation of neurotensin I receptors also involves conjoint activity
of D2 receptors and glutamatergic synaptic transmission leading
to eCB actions (Yin et al., 2008). Thus, several neurotransmitters
and neuromodulators appear to play key roles in DA stimulation
of eCB-mediated retrograde signaling. The synaptic depression
involving D2 activation in the presence of relatively moderate
synaptic activation is fully reversiblewhen agonist is removed from
the slice, and can thus be characterized as STD (Yin and Lovinger,
2006).
CORTICOSTRIATAL LONG-TERM DEPRESSION
The bulk of work on eCB-mediated synaptic plasticity in stria-
tum has focused on LTD at glutamatergic synapses. Analysis of
CB1 mRNA expression patterns indicates that CB1 receptors are
present in deep-layer cortical projection neurons (Marsicano and
Lutz, 1999). In contrast, extra-cortical areas that also supply gluta-
matergic input to the dorsal striatum, the thalamic parafascicular
nucleus and central medial, paracentral, and centrolateral thal-
amic complex, are devoid of any detectable CB1 mRNA signal
(Marsicano and Lutz, 1999) and their striatal afferents do not
immunostain for CB1 protein (Uchigashima et al., 2007). Thus,
eCB/CB1-mediated plasticity at glutamatergic striatal synapses is
most likely restricted to corticostriatal inputs.
Studies beginning in the early 1990s showed that high fre-
quency afferent stimulation in striatal slices induces a long-lasting
decrease in the amplitude of single stimulus-evoked glutamatergic
excitatory postsynaptic potentials or currents measured in MSNs
(Calabresi et al., 1992; Lovinger et al., 1993; Walsh, 1993). This
is a Hebbian form of lasting synaptic plasticity, with induction
requiring high frequency afferent stimulation coupled with post-
synaptic depolarization (HFS; Calabresi et al., 1992; Choi and
Lovinger, 1997a; Figure 1). eCB-LTD at glutamatergic synapses
involves the postsynaptic activation of (group 1) metabotropic
glutamate receptors (mGluRs), likely combined with concurrent
activation of L-typeVGCCs secondary to postsynaptic depolariza-
tion (Choi and Lovinger, 1997a; Gubellini et al., 2001; Wang et al.,
2006). These postsynaptic events stimulate retrograde synaptic sig-
naling (Choi and Lovinger, 1997a,b), involving the production
and release of eCBs that signal to presynaptically localized CB1
receptors (Gerdeman et al., 2002; Robbe et al., 2002; Kreitzer and
Malenka, 2005; Figure 1). CB1 receptors couple toGi/oG-proteins
which,upon receptor activation, likely inhibitVGCCs and adenylyl
cyclase activity in the presynaptic terminal.Maintained expression
of eCB-LTD may require adenylyl cyclase inhibition and decreased
production of cAMP, resulting in a decrease in the probability of
glutamate release (Heifets et al., 2008; Mato et al., 2008). Corticos-
triatal eCB-LTD is also pharmacologically inducible with agonists
of mGluRs or L-type VGCC activators (Kreitzer and Malenka,
2005; Adermark and Lovinger, 2007).
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FIGURE 1 | Mechanisms of corticostriatal long-term depression (LTD).
Four, one second bouts of afferent (corticostriatal, CTX) stimulation at
100Hz (high frequency stimulation, HFS) synchronized with postsynaptic
medium spiny neuron (MSN) depolarization (depol.) to 0 mV every ten
seconds induces endocannabinoid (eCB)-mediated LTD (eCB-LTD).
Induction of eCB-LTD involves metabotropic glutamate receptor (mGluR)
activation as well as suppression of cholinergic tone that requires
dopamine (DA) D2 receptor activation on tonically active cholinergic
interneurons (TANs). Relief of cholinergic tone on M1 acetylcholine (ACh)
receptors, coupled with postsynaptic depolarization, enhances activation
of L-type voltage-gated calcium channels (VGCCs) resulting in calcium
inﬂux (Ca2+). This triggers eCB production and subsequent liberation of
eCBs that signal retrogradely to activate presynaptic cannabinoid type 1
receptors (CB1), resulting in a persistent suppression of glutamate
release. Adenosine A2A receptors also play a role in eCB-LTD, with current
evidence indicating the location of action on bothTANs and D2 receptor
expressing (indirect pathway) MSNs. A balance between A2A and D2
receptor activation may govern downstream effectors modulating eCB
production, including PKA/cAMP and RGS4, which in turn regulate
mGluR5-induced signaling. The role of A2A receptors on presynaptic
terminals is presently unclear. Serotonin (5-HT) modulation of substantia
nigra pars compacta DA cell ﬁring and excitation of TANs likely inﬂuences
this form of plasticity. Moreover, serotonergic activation of corticostriatal
5-HT1b receptors induces LTD that is mutually occlusive with eCB-LTD.
Thus, a complex interplay of several neurotransmitter systems
orchestrates the ﬁne tuning of the corticostriatal synapse.
D2 DA RECEPTOR DEPENDENCE
The mechanisms underlying HFS-induced corticostriatal eCB-
LTD are similar to LTD observed at GABAergic and glutamater-
gic synapses in many brain regions (Lovinger, 2008; Heifets and
Castillo, 2009). However, the situation in striatum is further com-
plicated by the involvement of DA and D2 receptors in eCB-LTD
induction.Calabresi et al. (1992,1997) initially showed that striatal
glutamatergic LTD is lost followingDAdepletion,or after blockade
or knockout of D2Rs, and this ﬁnding has been widely repeated
(Tang et al., 2001; Kreitzer and Malenka, 2005, 2007; Wang et al.,
2006). But where in the striatalmicrocircuitry is the site of D2 acti-
vation that is crucial for eCB-LTD? A recent study suggested that
one possible site may be the tonically active cholinergic interneu-
rons (TANS; Wang et al., 2006). These investigators discovered
that the ability of D2 receptors on TANS to “pause” the activity
of, and thereby reduce ACh release from the cholinergic neuron,
relieves an inhibitory cholinergic tone on M1 receptor-expressing
MSNs. This tone appears to involve M1 suppression of L-type
VGCC function in MSNs (Figure 1). Relieving this tonic inhibi-
tion with M1 blockers promotes eCB production and subsequent
release. Consistent with this idea, bothCalabresi and Surmeier lab-
oratories showed that bath application of pirenzepine depresses
baseline corticostriatal glutamatergic transmission (Wang et al.,
2006; Tozzi et al., 2011), a ﬁnding that is refuted by Kreitzer and
Malenka (2007). This M1 activation induced effect is blocked by a
CB1 antagonist (Wang et al., 2006). One of the attractive aspects of
a role for the cholinergic system inmodulating corticostriatal eCB-
LTD is that it indicates a potential consequence of the burst TAN
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activity followed by a pause in ﬁring during incentivized behaviors
(Shimo and Hikosaka, 2001). HFS then theoretically represents
the “burst” phase and, through subsequent D2 receptor-mediated
inhibition of TAN activity, also induces the pause epoch. Thus,
eCB-LTD in this context may be implicated as a form of plasticity
underlying incentivized learning.
The other possible site of D2 activation is the D2-expressing
indirect pathway MSN. Supporting this idea, evidence emerged
indicating that eCB-LTD is restricted to glutamatergic synapses
onto indirect pathway MSNs, in contrast to direct pathway MSNs
that express D1 in preference to D2 receptors, when assessed
using the classic HFS protocol and microstimulation (Kreitzer and
Malenka, 2007). Subsequently, Surmeier’s group provided further
evidence, using a negative spike-timing-dependent protocol, that
it is possible to observe eCB-LTD only in D2 MSNs (Shen et al.,
2008). This further implicated theD2 receptor on indirect pathway
MSNs in eCB-LTD as activation of a TAN-localized D2 receptor
should theoretically induce eCB-LTD equally in both D1 and D2
MSNs (see Wang et al., 2006). Despite these interesting ﬁndings,
no direct evidence yet exists supporting or refuting the role of D2
receptor activation on indirect pathway MSNs in eCB-LTD.
Whether activation of D2 receptors located onTANs or indirect
pathway MSNs, or both, contribute to eCB-LTD, it is important
to remember that D2 activation plays a modulatory, not a neces-
sary role per se. This is illustrated by the ﬁnding that activation of
mGluRs (Kreitzer and Malenka, 2005) or L-type VGCCs alone
induce eCB-LTD that occludes HFS-induced LTD and occurs
in the presence of a D2 antagonist (Adermark and Lovinger,
2007). It was recently shown in indirect pathway MSNs that
(microstimulator-delivered) HFS-induced calcium entry through
L-type VGCCs induces an intracellular calcium release that ulti-
mately results in the production of AEA as the eCB signaling
molecule mediating this form of eCB-LTD (Ade and Lovinger,
2007; Lerner and Kreitzer, 2012). Complicating the picture, mod-
erate frequency (10–20Hz) stimulation-induced eCB-LTD, which
is known to be calcium independent (Ronesi and Lovinger, 2005),
was shown to be 2-AG-mediated (Lerner and Kreitzer, 2012). In
light of the calcium-independence of this form of eCB-LTD, the
degree of its demonstrated D2 receptor-dependence begs further
inquiry (Lerner and Kreitzer, 2012).
If indirect pathway MSN D2 receptors are involved in eCB-LTD
induction, what signaling pathways mediated by these receptors
link them to eCBproduction?One possibility is activation of phos-
pholipase C via Gβ/γ signaling (Lee et al., 2004; Pollack, 2004).
However, the PLC signaling pathway is thought to involve coop-
erative D1 and D2 receptor actions, contrasting with the usual
segregation of these receptors onto different MSN subpopula-
tions as well as the separate roles of these receptors in LTP and
LTD. Furthermore, there is little or no direct evidence that D2
activation leading to phospholipase stimulation actually occurs in
MSNs. Inhibition of adenylyl cyclase by D2 receptors could also
contribute to eCB production (Kheirbek et al., 2009; Lerner and
Kreitzer, 2012). Indeed, Kheirbek et al. (2009) have suggested that
this involves inhibition of the adenylyl cyclase 5 isoform impli-
cated in LTD. Interestingly, Lerner and Kreitzer (2012) suggest
a key role in LTD induction for the regulator of G protein sig-
naling 4 (RGS4) protein that is a potential downstream target
of cAMP/PKA signaling. The roles of these signaling pathways
remain to be determined when LTD is induced with different
stimulus paradigms and in direct pathway MSNs.
ADENOSINE A2A RECEPTOR MODULATION
Data now exists indicating a role for the adenosine A2A recep-
tor in eCB-LTD modulation. The Surmeier group showed that a
competitive interaction exists between the A2A and the D2 DA
receptor in the induction of spike-timing-dependent eCB-LTD
(Shen et al., 2008). They showed that the negative timing protocol-
induced LTD in D2 MSNs is governed by a balance between
D2 and A2A receptor activation, such that D2 blockade abol-
ishes LTD, but D2 blockade with combined A2A activation allows
for LTP induction (Shen et al., 2008). This opposing interaction
between D2 and A2A was recently supported by ﬁndings showing
that (microstimulator-delivered) HFS- and moderate frequency-
induced eCB-LTD in D2 MSNs is blocked by D2 blockade or
A2A activation (Lerner and Kreitzer, 2012). Thus, D2 receptor
activation promotes LTD, while A2A activation promotes LTP.
Further supporting the interaction between DA and adenosine
systems in eCB-LTD, the Calabresi group demonstrated that D2
DAreceptor activation alonedoesnot induce striatal glutamatergic
synaptic depression, but does induce plasticity when anA2A recep-
tor antagonist is co-applied to striatal slices (Tozzi et al., 2011). This
synaptic depression is disrupted by CB1 receptor blockade. While
D2 and A2A receptors are expressed by indirect pathway MSNs,
qPCR data deﬁnitively shows co-expression of these receptors on
TANs (Song et al., 2000), and this is supported by other ﬁnd-
ings (Brown et al., 1990; James and Richardson, 1993; Tozzi et al.,
2011). This again begs the question of whether the site of action
of D2 activation/A2A inhibition-induced glutamatergic synaptic
depression is on TANs or indirect pathway MSNs (Figure 1).
Supporting a role for the cholinergic interneuron, only the spe-
ciﬁc combination of D2 activation/A2A inhibition suppresses TAN
ﬁring activity. Furthermore, this drug-induced depression of glu-
tamatergic synapses is blocked (or occluded) in the presence of an
M1 muscarinic antagonist (Tozzi et al., 2011), and this receptor is
reportedly expressed on both direct and indirect pathway MSNs.
As such, this eCB-dependent form of synaptic depression is likely
expressed at corticostriatal synapses onto both direct and indirect
pathway MSNs (Tozzi et al., 2011). It should be noted, however,
that inducing synaptic depression by drug application may not be
recruiting the same mechanisms recruited by the HFS protocol
classically used to induce eCB-LTD.
Further complicating the role of the A2A receptor in modu-
lating eCB-LTD, anatomical evidence now exists demonstrating
the presence of this receptor on glutamatergic terminals contact-
ing direct pathway MSN dendritic spines (Quiroz et al., 2009).
Activation of A2A receptors alone with CGS21680 increases gluta-
matergic transmission onto direct pathway MSNs, while blockade
of these receptors decreases release (Quiroz et al., 2009). Interest-
ingly, applying a signiﬁcantly lower concentration of CGS21680 by
itself has no effect, but in the presence of a CB1 agonist, partially
inhibits the CB1-mediated suppression of glutamatergic transmis-
sion (Martire et al., 2011). Taken together, these ﬁndings suggest
a possible role for direct A2A modulation of the corticostriatal
synapse alone or in combination with CB1 receptors.
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NITRIC OXIDE
Studies have also implicated the gaseous neuromodulator nitric
oxide (NO) in striatal synaptic plasticity. Roles for NO in synap-
tic plasticity in hippocampus, cerebellum, and other brain regions
had been postulated since the early 1990s (Schuman and Madi-
son, 1991), but the subject has not been without controversy (see
Zorumski and Izumi, 1993;Malenka andBear, 2004). Experiments
in theCalabresi laboratory have indicated thatNOS inhibitors pre-
vent LTD induction (Calabresi et al., 1999; Bagetta et al., 2011),
while data from the Haas laboratory provide a more confusing
picture of the NOS role in LTD. These investigators originally
reported that the occurrence of HFS-induced LTD was enhanced
by NOS inhibition and in eNOS knockout mice (Doreulee et al.,
2003). A subsequent report from the same group showed that
LTD induced by group I mGluR-activation was converted to STD
in the presence of a NOS inhibitor or in eNOS knockout mice
(Sergeeva et al., 2007), while CB1 antagonists blocked LTD alto-
gether. These investigators also showed that an LTD-like decrease
in evoked synaptic responses could be induced by application of
NOdonors.One prominentmolecular target of NO is the striatally
enriched soluble guanylate cyclase (GC), suggesting the possibility
that activation of this enzyme and subsequent cGMP formation
might be sufﬁcient to induce LTD. Indeed, Calabresi et al. (1999)
have demonstrated that the cGMP phosphodiesterase inhibitor
zaprinast, and intracellular application of cGMP itself, can induce
long-lasting synaptic depression during low-frequency synaptic
activation. Intracellular application of a soluble GC inhibitor pre-
vents LTD induced by HFS or NO donor application. Protein
kinase G activation would be expected to result from activa-
tion of this signaling cascade, and a PKG inhibitor was shown
to prevent LTD (Calabresi et al., 1999). This pharmacologically
induced depression occludes HFS-induced LTD, consistent with
overlapping mechanisms of induction/expression.
Several questions remain about how NO signaling participates
in striatal LTD and the nature of the relationship between NO,
DA, and eCBs in LTD. Calabresi et al. (1992, 1999) have reported
that antagonists of D1-likeDA receptors prevent LTD induction by
HFS. Further investigation revealed that LTD was intact in gene-
targeted knockout mice lacking the D1 receptor (Centonze et al.,
2003). However, in mice lacking the D1 receptor, a D1-like antag-
onist still prevented HFS-induced LTD, suggesting involvement of
D5 receptors (Centonze et al., 2003). Experiments demonstrat-
ing that D5 receptors are expressed by striatal interneurons that
express NO synthase (NOS) led these investigators to postulate
that the role of D5 receptors in LTD might involve NO produc-
tion by these neurons. Additional direct evidence for a D5 role
in eCB-LTD would provide stronger support for this idea. What
accounts for the apparent variability in NO involvement when
LTD is induced by different means in the Haas laboratory papers?
It should be noted that these investigators examined LTD solely in
ﬁeld potential recordings where the synaptically driven ﬁring of
striatal neurons is the onlymeasurement. This is at best an indirect
measure of synaptic efﬁcacy. Thus, it is possible that mechanisms
other than changes in glutamatergic synaptic efﬁcacy account for
their ﬁndings. In the context of this review, it is not clear if NO and
eCBs act separately or in concert to induce or facilitate LTD. The
fact that NOS inhibitors and CB1 antagonists have been reported
to completely eliminate LTD would suggest that both are neces-
sary and likely act via part of the same mechanism. However, the
fact that STD induced by the mGluR agonist DHPG remains in
the presence of the NOS inhibitor provides a potential clue to
the sequence of mechanisms involving these neuromodulators.
Perhaps cCBs stimulate NO production that is then required for
maintained LTD, which is suggested as one possibility by Sergeeva
et al. (2007). However,NOS inhibitor exposure prevents induction
of HFS-induced LTD (Calabresi et al., 1999), making this scenario
seem less plausible. It must be noted that some investigators have
reported evidence consistent with the idea that NO increases cor-
tical activation of MSN ﬁring (West and Grace, 2004; Ondracek
et al., 2008), and of course there is the work implicating NO in
LTP in several brain regions including hippocampus (Schuman
and Madison, 1991) and even striatum (Doreulee et al., 2003).
Thus, it is unclear why this effect would not counteract LTD upon
indiscriminate MSN sampling.
DIRECT VS. INDIRECT PATHWAY
As the ﬁeld marches forward, it is important to note that the
pathway speciﬁcity data gathered by Kreitzer and Malenka (2007)
runs counter to the ﬁndings of other laboratories (Wang et al.,
2006; Bagetta et al., 2011). Differences in stimulation electrode size
(micro vs. macro) have been hypothesized as the reason for this
discrepancy. Kreitzer and Malenka (2007) used a microstimulator,
arguing thatmacrostimulation results in eCBoverﬂow fromneigh-
boring cells, therefore resulting in direct pathway MSN eCB-LTD
(Kreitzer and Malenka, 2008). Supporting this, a negative timing
protocol, where repeated theta bursts of postsynaptic cell spiking
precede afferent theta burst activation induced by a microstimu-
lator, induces eCB-LTD at indirect, but not direct pathway MSNs
(Shen et al., 2008).
Using macrostimulation, evidence continues to mount sup-
porting theoccurrenceof eCB-LTDat corticostriatal synapses onto
both direct and indirect pathway MSNs. A recent study from the
Calabresi laboratory observed eCB-LTD inbothdirect and indirect
pathway cell types using intracellular biocytin and immunola-
beling for either substance P (direct pathway) or A2A receptor
(indirect pathway; Bagetta et al., 2011). Intriguingly, they did not
observe eCB-LTD at direct pathway MSNs upon recording from
GFP-positive cells in slices taken from D1-eGFP BAC transgenic
mice. However, they observed eCB-LTD in GFP-negative MSNs in
slices taken from D2-eGFP BAC transgenic mice (Bagetta et al.,
2011). The authors conclude that an alteration of D1 DA recep-
tor signaling, secondary to eGFP expression, may be blocking the
expression of eCB-LTD. Direct evidence of such an assertion is still
needed, however. In light of the requirement for D1 DA receptor
antagonism to achieve negative timing-induced eCB-LTD at direct
pathway MSNs (using a microstimulator; Shen et al., 2008), alter-
ation of D1 DA receptor signaling in the D1-eGFP BAC transgenic
mouse may explain the loss of eCB-LTD in eGFP-positive MSNs
of these animals (Bagetta et al., 2011). Though the recordings
showing a lack of eCB-LTD in eGFP-positive MSNs in D1-eGFP
BAC mice calls into question the pathway speciﬁcity claims of
eCB-LTD, the substantial differences in techniques used by the
different investigators leave open the possibility that speciﬁcity
occurs under certain experimental conditions.
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Rather than a clear preference for one pathway, a possible bias
may exist for plasticity to occur at indirect over direct pathway
MSNs. Ultimately, it will be useful to know if eCB-LTD occurs
at corticostriatal synapses in vivo, and if so, is there pathway
speciﬁcity related to behavior.
STRIATAL GABAergic SYNAPTIC PLASTICITY
Examination of GABAergic synapses onto striatal MSNs has also
revealed eCB-mediated synaptic depression, including LTD (Szabo
et al., 1998; Narushima et al., 2006b; Adermark et al., 2009). Kano
and colleagues have found small-magnitude DSI following MSN
depolarization (Narushima et al., 2006b, 2007). This group has
also observed signiﬁcant short-lasting synaptic depression fol-
lowing combined postsynaptic depolarization and activation of
muscarinic acetylcholine receptors (Narushima et al., 2007). In
this context, it is also worth noting the work of Maccarrone
and coworkers that has implicated eCBs in synaptic depression
at GABAergic inputs to MSNs triggered by D2 receptor activation
(Centonze et al., 2004). These investigators observed thatGABAer-
gic synaptic transmission is depressed by application of cocaine
or a D2 receptor agonist to striatal slices. Synaptic depression is
accompanied by a decrease in the frequency of spontaneous IPSCs,
suggesting a presynapticmechanism of the cocaine andD2 agonist
actions. The cocaine-induced synaptic depression is prevented by
D2 antagonists, and reduced by CB1 antagonists, and CB1 ago-
nist application produces synaptic depression (Szabo et al., 1998;
Narushima et al., 2006a; Adermark et al., 2009). Application of
cocaine or D2 agonist to slices also increases tissue AEA levels
(Centonze et al., 2004). Thus, eCBs and CB1 receptors have cru-
cial roles in short-lasting synaptic depression produced by various
stimuli.
In contrast to the high frequencies of synaptic activation used
to induce glutamatergic eCB-LTD, LTD at GABAergic synapses is
activated at low stimulus frequencies (1–5Hz).Moreover, depolar-
ization of the postsynaptic cell is not necessary to induce eCB-LTD
atGABAergic synapses, as it is at glutamatergic synapses. The lower
threshold for eCB-LTD induction at inhibitory synapses is likely a
reﬂection of the signiﬁcantly higher expression of CB1 on striatal
GABAergic terminals relative to their glutamatergic counterparts
(Uchigashima et al., 2007). However, similar to the glutamatergic
synapses, activation of mGluRs and VGCC currents are impli-
cated in GABAergic eCB-LTD (Adermark et al., 2009). It is not yet
clear if DA plays a role in this form of plasticity. In addition, it
is not known whether this GABAergic eCB-LTD occurs at MSN–
MSN or fast-spiking interneuron-MSN synapses, both of which
are inhibitory and contain presynaptic CB1 (Freiman et al., 2006;
Uchigashima et al., 2007). What we do know is that the net effect
of eCB-LTD at GABAergic and glutamatergic synapses appears to
be disinhibition and inhibition of MSN activation, respectively.
These opposing effects create a situation in which striatal output
can be modulated as a consequence of glutamatergic input in a
frequency-dependent manner (Adermark and Lovinger, 2009). It
will be interesting to determine if dopaminergic modulation adds
another level of complexity to this dual-plasticity scenario.
SEROTONIN AND DA/eCB STRIATAL SYNAPTIC PLASTICITY
In addition to the dense striatal dopaminergic innervation, sero-
tonergic ﬁbers arising from the dorsal raphe nucleus also project
to the dorsal striatum. Existing data on serotonin (5-HT) effects
on striatal function suggest interplay between 5-HT and DA sys-
tems. 5-HT acts at multiple points in the striatal machinery crit-
ical for DA-dependent eCB-LTD, having effects on dopaminergic
nigrostriatal cells, striatal TANS, and corticostriatal terminals.
Such a tight interaction between both monoaminergic sys-
tems would suggest a level of functional competition. This idea
is supported by the observation that neonatal DA depletion in rats
results in serotonergic hyperinnervation selectively in the striatum
(Breese et al., 1984; Stachowiak et al., 1984). Surprisingly, these ani-
mals are not akinetic in adulthood, but are hyperactive (Shaywitz
et al., 1976; Erinoff et al., 1979; Luthman et al., 1989). This observa-
tion would suggest that intact striatal function is dependent upon
a dynamic interplay between the dopaminergic and serotonergic
signaling systems. Supporting this notion, Mathur et al. (2011)
showed that application of 5-HT or a 5-HT1b receptor agonist
induces LTD of glutamate release. Evidence supports a presynap-
tic locus of expression of this form of LTD and a presynaptic
localization of 5-HT1b (Mathur et al., 2011). This study showed
that blockade of 5-HT reuptake with a selective 5-HT reuptake
inhibitor coupled with a burst stimulation protocol induces a 5-
HT1b dependent depression of corticostriatal glutamate release.
This endogenous 5-HT-LTD is mutually occlusive of eCB-LTD,
demonstrating a direct interaction of 5-HT and DA-dependent,
CB1-mediated control of corticostriatal glutamate release (Mathur
et al., 2011).
The serotonergic innervation of the human striatum appears
heterogeneous (Wallman et al., 2011), a ﬁnding that may carry
important implications for serotonergic control of selected
actions. These 5-HT innervation poor zones are also weak in tyro-
sine hydroxylase immunostaining (Wallman et al., 2011). Thus,
one conclusion might be that such zones may correspond to
striosomes (Wallman et al., 2011), in which case 5-HT signaling
may have a greater affect on matrix/motor-associated processing
(Crittenden and Graybiel, 2011). It should be noted, however,
that the study by Wallman et al. (2011) did not control for cell
population density or white matter composition, nor did they
co-immunostain for a striosomal marker. As such, substantive
links between serotonergic innervation heterogeneity and action
control are lacking. However, the co-innervation of striatum
by dopaminergic and serotonergic ﬁbers underscores the poten-
tial interplay between these systems and carries implications for
striatal disorders involving DA dysfunction.
Other targets of 5-HT may also directly inﬂuence eCB-LTD.
Exogenous or endogenous 5-HT increases the spontaneous ﬁr-
ing rate of rat striatal TANs (Blomeley and Bracci, 2005; Bonsi
et al., 2007). Considering the data supporting a role for relief of
M1 receptor activation in eCB-LTD induction, 5-HT-mediated
activation of TANS could increase the threshold for eCB-LTD
induction (Wang et al., 2006; Figure 1). 5-HT may also be mod-
ulating striatal DA release, representing another level of DA and
5-HT interaction inﬂuencing eCB-LTD. Genetic deletion of the
5-HT2c receptor increases burst ﬁring of substantia nigra pars
compacta dopaminergic neurons and increases the frequency of
spike trains (Abdallah et al., 2009). Matching this enhancement,
dorsal striatal DA concentrations in 5-HT2c knockouts are signiﬁ-
cantly elevated. Given the critical role of DAD2 receptor activation
in eCB-LTD, serotonergic modulation of nigrostriatal DA release
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may exquisitely inﬂuence this form of plasticity. Thus, multiple
levels of interaction between 5-HT and DA systems exist that
may be necessary for the proper tuning of corticostriatal synaptic
transmission.
PATHOPHYSIOLOGY
Parkinson’s disease is a progressive neurodegenerative disorder
that is characterized by a loss of neurons in the substantia nigra
that supply the dopaminergic innervation to the dorsal striatum.
PD is effectively treated with levodopa (or l-DOPA), the biosyn-
thetic pathway precursor molecule to DA. However, prolonged
l-DOPA treatment results in side effects involving abnormal invol-
untary movements, or dyskinesia. Since the dorsal striatum is
richly endowed with a dopaminergic innervation, and neuronal
degeneration preferentially occurs in substantia nigra as opposed
to the ventral tegmental area in PD, cell loss dramatically affects
the dorsal striatum. Given that corticostriatal eCB-LTD is D2
receptor dependent, the profound implication is that this form
of synaptic plasticity is lost as striatal DA content diminishes, pos-
sibly contributing to the cardinal PD clinical features of tremor,
rigidity, and bradykinesia. eCB-LTD is indeed lost upon stri-
atal DA depletion (Calabresi et al., 1992; Kreitzer and Malenka,
2007). Furthermore, corticostriatal eCB-LTD is implicated in the
development of l-DOPA-induced dyskinesia (LID). Picconi et al.
(2011) showed that non-dyskinetic parkinsonian rats (treatedwith
l-DOPA) expressed eCB-LTD,while dyskinetic rats did not. Phos-
phodiesterase inhibition restores eCB-LTD in these dyskinetic rats
and alleviates the occurrence of dyskinetic behaviors (Picconi et al.,
2011). Thus, eCB-LTD is positioned as a key target for therapeutic
intervention in PD.
Unlike the progressive degeneration of striatal dopaminergic
innervation seen in PD, striatal serotonergic innervation is rela-
tively spared and,upon treatmentwith levodopa (or l-DOPA), this
innervation is enriched (Rylander et al., 2010). Striatal serotoner-
gic ﬁbers synthesize and release l-DOPA-derived DA; this ectopic
DA release is responsible for the development of LID (Carta et al.,
2007). Interestingly, serotonergic neuronautoreceptor (5-HT1a/b)
agonists possess efﬁcacy in alleviating LID (Carta et al., 2007). In
light of the host of studies now supporting a role for the dysregu-
lation of corticostriatal glutamatergic signaling in the occurrence
of LID (Huot and Brotchie, 2011), it is tempting to speculate that
the mechanism of action underlying 5-HT1b agonist efﬁcacy for
the treatment of LID is the dampening of corticostriatal gluta-
mate release. This idea is consistent with the ﬁndings by Picconi
et al. (2011) showing a loss of eCB-LTD only in l-DOPA-treated
parkinsonian rodents that express LID.
The striatal DA depletion seen in PD also induces a dra-
matic MSN dendritic dysmorphology (Zaja-Milatovic et al., 2005;
Deutch et al., 2007). Speciﬁcally, a signiﬁcant pruning of den-
dritic spines occurs, culminating in the loss of corticostriatal
synapses. The Surmeier laboratory elegantly showed that this den-
dritic pruning is restricted to indirect MSNs (Day et al., 2006).
It is interesting to speculate that if eCB-LTD is restricted to the
indirect pathway (Kreitzer and Malenka, 2007) that the loss of
corticostriatal synapses onto these cells contributes to an inabil-
ity to detect eCB-LTD in the parkinsonian state. However, this
would seem unlikely given that both the Malenka and Surmeier
laboratories showed that DA-denervation-induced impairment of
eCB-LTD in D2 MSNs is restored simply by bath applying a D2
agonist (Kreitzer and Malenka, 2007; Shen et al., 2008). This ﬁnd-
ing would imply that the most parsimonious reason for the loss
of eCB-LTD, at least in D2 MSNs, in the DA denervated state
is loss of D2 receptor activation. Interestingly, timing-dependent
induction of LTD is observed in D1 MSNs only in the presence
of a D1 receptor antagonist or in the DA denervated state (Shen
et al., 2008). This ﬁnding raises the interesting question of why
eCB-LTD induced with HFS in D1 MSNs or MSNs sampled indis-
criminately is blocked in the presence of a D2 antagonist or in the
DA denervated state (Calabresi et al., 1992;Wang et al., 2006). This
issue again highlights the caveat that different plasticity induction
protocols are employed across different studies and laboratories
and that both D1 and D2 MSNs are not always discriminated dur-
ing sampling. For instance, it would be interesting to see if the
induction protocol used in the Kreitzer and Malenka (2007) study
evokes eCB-LTD in direct pathway MSNs in the DA denervated
state.
Clearly, more work is needed to determine the contribution of
eCB-LTD onto D1 and D2 MSNs to parkinsonism. Nevertheless,
advances in targeting eCB-LTD of corticostriatal synapses may
have already been realized. For instance, muscarinic antagonists
have been utilized for years as treatment for PD (Chen and Swope,
2007), which would support the idea that cholinergic tone is an
important modulator of eCB-LTD. Speciﬁcally regarding the M1
receptor, antagonists of this target yield a mild improvement in
motor symptoms in PD animal models, but fail to achieve the efﬁ-
cacy seenwith broadmuscarinic antagonist administration (Xiang
et al., 2012). This ﬁnding would suggest that muscarinic activation
at other basal ganglia synapse types are importantly modulated by
this receptor class. Regarding the role of adenosine, administration
of an A2A antagonist to reserpine-treated mice prevents reserpine-
induced catalepsy (Peterson et al., 2012). Considering the eCB
system, but perhaps not the corticostriatal synapse in particular,
ﬁndings in DA-depleted animals indicate that motor dysfunction
is alleviated by inhibiting eCB metabolism with systemic injection
of a FAAH inhibitor in mice (Kreitzer and Malenka, 2007). Finally,
data now implicate a role for the RGS4 protein in modulating eCB
production in indirect pathway MSNs: inhibiting RGS4 restores
eCB-LTD in the presence of a D2 antagonist and DA denervated
RGS4nullmice are resistant to some features of motor dysfunction
typical of parkinsonism (Lerner and Kreitzer, 2012).
While the striatal hypodopaminergic state results in a paucity
of action initiation, it is suggested that aberrant, and perhaps
enhanced, mesostriatal DA signaling is an important component
in the formation of repeated, habitual actions seen in addiction
to drugs that act on DA signaling, such as cocaine or amphet-
amine (Lovinger et al., 2003). A role for DA signaling in the
learning of motor sequences is now established. Upon learning
a ﬁxed-ratio of eight lever presses to earn a food reward, sub-
stantia nigra dopaminergic cells ﬁre most vigorously during the
initiation and termination of the entire lever-pressing sequence
(Jin and Costa, 2010). This ﬁnding may explain the action ini-
tiation and termination deﬁciency seen in PD, and reinforces the
concept of dopaminergic control of striatal-mediated action learn-
ing and control. Implicating striatal DA-dependent eCB-LTD in
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action learning, genetic deletion of CB1 or systemic pharmacolog-
ical blockade of this receptor disrupts habit formation, a behavior
dependent upon the dorsolateral striatum (Hilário et al., 2007).
CONCLUSION
Though the last two decades have seen considerable advances in
our knowledge of DA modulation of eCB-LTD at the corticos-
triatal synapse, more work is needed to fully characterize this
plasticity system.Currently, the core issues requiring consensus are
the site of action of the D2 DA receptor and the pathway speciﬁcity
of this formof synaptic plasticity.As detailed above,data generated
from various laboratories offer discrepant conclusions regarding
these issues. It is important to remember, however, that the meth-
ods used to generate these divergent data vary from laboratory to
laboratory. Thus, the literaturemay accurately reﬂect the capability
of the system, but determining when and under what conditions
these varying outcomes are expressed in vivo represents the major
challenge for future investigation of corticostriatal eCB-LTD.
As the molecular and circuit mechanisms of eCB-LTD are fur-
ther elucidated, another major challenge will be to determine
the contribution of eCB-LTD to action learning. We really have
only scratched the surface of this issue (Hilário et al., 2007). In
the future, applying knowledge derived from in vitro analyses to
in vivo manipulation of this system using conditional knockout
and optogenetic approaches, for example, combined with sophis-
ticated behavioral measures will be necessary to fully describe
the roles of this plasticity in physiological and pathophysiological
states.
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